Patent ID: 8088389
Filing Date: 2012-01-03
Classification: A61K,A61P,C07K

Abstract:
1. A synthetic polypeptide consisting of (i) amino acid sequences of at least two immunogenic epitopic clusters (hereinafter IECs) of each of at least three different human autoantigens related to human multiple sclerosis selected from the group consisting of myelin-associated glycoprotein (MAG), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG), myelin-oligodendrocytic basic protein (MOBP), oligodendrocyte-specific protein (OSP) and proteolipid protein (PLP), each said IEC consisting of a region of a said autoantigen containing (a) an immunogenic epitope or (b) a collection of immunogenic epitopes, wherein (A) at least two of the IECs of the polypeptide are selected from the group consisting of the amino acid sequences 1-25 (SEQ ID NO:135), 32-58 (SEQ ID NO:136) and 63-97 (SEQ ID NO:137) of MOG; (B) at least two of the IECs of the polypeptide are selected from the group consisting of the amino acid sequences 7-50 (SEQ ID NO:138), 83-106 (SEQ ID NO:139), and 142-168 (SEQ ID NO:140) of MBP; and (C) at least two of the IECs of the polypeptide are selected from the group consisting of the amino acid sequences 30-60 (SEQ ID NO:141), 84-116 (SEQ ID NO:142) and 139-155 (SEQ ID NO:143) of PLP, and (ii) optional synthetic spacers, wherein each said IEC is fused contiguously to, or separated by a synthetic spacer from, each adjacent IEC, wherein, no two adjacent IECs, either fused in contiguity or separated by a synthetic spacer, together form a contiguous sequence within any of said autoantigens, and wherein one or more cysteine residue in a native IEC is optionally substituted by a serine residue, provided that any said Cys→Ser substituted IEC improves the solubility of the native IEC.